Laparoscopic Pancreatoduodenectomy Versus Open Pancreatoduodenectomy

August 29, 2022 updated by: Renyi Qin, Tongji Hospital

Minimally Invasive Versus Open for Pancreatoduodenectomy:an Retrospective, Observational, Multicenter Real-world Study

This is a single, retrospective, real-world study to investigate the surgical outcomes of minimally invasive pancreatoduodenectomy and open pancreatoduodenectomy, with the perioperative characteristics and long-term overall survival being compared. The investigators aimed to find out whether the minimally invasive surgery is safe and feasible for resectable lesions located in the pancreatic head and periampullary region. And the investigators also want to find out patients with what kind of characteristic can be benefit from the minimally invasive surgery compared with the open approach.

Study Overview

Detailed Description

Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region.To date, how surgeons can safely pass the learning curve of laparoscopic pancreatoduodenectomy (LPD) without potentially harming patients remains a question. Around this topic, the investigators designed real-world study in a single center to retrospectively collect the PD surgeries since July 2014. The investigators aimed to find out whether the minimally invasive surgery is safe and feasible for resectable lesions located in the pancreatic head and periampullary region. And the investigators also want to find out patients with what kind of characteristic can be benefit from the minimally invasive surgery compared with the open approach. Besides, the investigators also want to investigate the clinical characteristics of patients and perioperative outcomes of LPD procedures and aimed to develop and validate a difficulty scoring system for patient selection which could help facilitate a comprehensive and security understanding of LPD for surgeon during different stage of the learning curve.

Study Type

Observational

Enrollment (Actual)

800

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who underwent PD surgeries in Tongji Hospital since January 2014 .

Description

Inclusion Criteria:

  1. Aged 18 to 80 years.
  2. Patients underwent PD surgeries.

Exclusion Criteria:

  1. Peritoneal seeding or metastasis to distant sites;
  2. Incomplete clinical data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
minimally invasive surgery
laparoscopic pancreatoduodenectomy.
Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
open surgery
open pancreatoduodenectomy
Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative length of stay
Time Frame: up to 90 days
defined as the time from being admitted to hospital to discharge
up to 90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: through study completion, an average of 5 year
defined as the duration from the first day after surgery to either the date of death or the last follow-up
through study completion, an average of 5 year
Operation time
Time Frame: intraoperative
defined as the time from skin incision or trocar placement to complete skin closure
intraoperative
postoperative complications
Time Frame: up to 90 days
Postoperative complications were reviewed within 90 days after surgery and graded according to Clavien-Dindo (CD) classification system. Postoperative biliary leakage, hemorrhage, and liver failure. Wound infection was defined as purulent drainage from the incision or/and positive findings of culture of the fluid or tissue aseptically obtained from the incision.
up to 90 days
Reoperation within 90 days
Time Frame: up to 90 days
defined as any reoperation within 90 days
up to 90 days
Mortality
Time Frame: up to 90 days
defined as any death within 30 days and 90 days, respectively
up to 90 days
Readmission within 90 days
Time Frame: up to 90 days
defined as any readmission within 90 days
up to 90 days
R0 resection
Time Frame: intraoperative
defined as tumor-free margins in all the reported surgical margins (biliary and circumferential margins
intraoperative
Intraoperative blood loss
Time Frame: intraoperative
recorded by the anesthetist using a vacuum system
intraoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2014

Primary Completion (Actual)

December 30, 2019

Study Completion (Actual)

December 30, 2021

Study Registration Dates

First Submitted

August 19, 2022

First Submitted That Met QC Criteria

August 29, 2022

First Posted (Actual)

August 30, 2022

Study Record Updates

Last Update Posted (Actual)

August 30, 2022

Last Update Submitted That Met QC Criteria

August 29, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • TJDBPS11

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Resectable Lesions Located in the Pancreatic Head or Periampullary Region

Clinical Trials on pancreatoduodenectomy

3
Subscribe